10-Patient Trial: Remarkable Responses in Pediatric Cancers.

A clinical trial of Nivolumab in 10 pediatric cancer patients with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair-based susceptibility.